Methods and compositions for improving fidelity in a nucleic acid synthesis reaction

Information

  • Patent Grant
  • 7482120
  • Patent Number
    7,482,120
  • Date Filed
    Friday, January 28, 2005
    19 years ago
  • Date Issued
    Tuesday, January 27, 2009
    15 years ago
Abstract
The invention provides methods and compositions for improving the fidelity of a sequencing-by-synthesis reaction by using a nucleotide derivative that forms a hydrogen bond with a complementary nucleotide on a template, but fails to form a phosphodiester bond with the 3′ hydroxyl group of a primer under conditions otherwise suitable for a polymerization reaction; thereby blocking incorporation of a mismatched nucleotide.
Description
TECHNICAL FIELD OF THE INVENTION

The invention generally relates to methods for improving fidelity in a nucleic acid synthesis reaction, and more particularly to methods for sequencing a nucleic acid using a nucleotide derivative that decreases the rate of misincorporation of nucleotides in a nucleic acid synthesis reaction.


BACKGROUND OF THE INVENTION

In vitro nucleic acid synthesis is a foundation of many fundamental research and diagnostic tools, such as nucleic acid amplification and sequencing. In a template-dependent nucleic acid synthesis reaction, the sequential addition of nucleotides is catalyzed by a nucleic acid polymerase. Depending on the template and the nature of the reaction, the nucleic acid polymerase may be a DNA polymerase, an RNA polymerase, or a reverse transcriptase. DNA synthesis requires a 3′ hydroxyl on the primer for addition at the α-phosphate of a free deoxynucleotide triphosphate (dNTP). A phosphodiester bond between the nucleotide on the 3′ terminus of the primer and the free nucleotide is formed and diphosphate is released. This reaction is shown schematically in FIG. 1.


The fidelity of template-dependent nucleic acid synthesis depends in part on the ability of the polymerase to discriminate between complementary and non-complementary nucleotides. Normally, the conformation of the polymerase enzyme favors incorporation of the complementary nucleotide. However, there is still an identifiable rate of misincorporation that depends upon factors such as local sequence and the base to be incorporated.


Synthetic or modified nucleotides and analogs, such as labeled nucleotides, tend to be incorporated into a primer less efficiently than naturally-occurring dNTPs. The reduced efficiency with which the unconventional nucleotides are incorporated by the polymerase can adversely affect the performance of sequencing techniques that depend upon faithful incorporation of such unconventional nucleotides.


Single molecule sequencing techniques allow the evaluation of individual nucleic acid molecules in order to identify changes and/or differences affecting genomic function. In single molecule techniques, individual, optically-resolvable nucleic acid fragments are attached to a solid support, and sequencing is conducted on the individual strands. Sequencing events are detected and correlated to the individual strands. See Braslavsky et al., Proc. Natl. Acad. Sci., 100: 3960-64 (2003), incorporated by reference herein. Because single molecule techniques do not rely on ensemble averaging as do bulk techniques, errors due to misincorporation can have a significant deleterious effect on the sequencing results. The incorporation of a nucleotide that is incorrectly paired, under standard Watson and Crick base-pairing, with a corresponding template nucleotide during primer extension may result in sequencing errors. The presence of misincorporated nucleotides may also result in prematurely terminated strand synthesis, reducing the number of template strands for future rounds of synthesis, and thus reducing the efficiency of sequencing.


There is, therefore, a need in the art for improved methods for reducing the frequency of misincorporation and improving fidelity in nucleic acid synthesis reactions, especially in single molecule sequencing.


SUMMARY OF THE INVENTION

The invention addresses the problem of misincorporations in nucleic acid synthesis reactions. The invention improves the fidelity of nucleic acid synthesis reactions by selectively blocking incorporation of non-complementary nucleotides in a template-dependent sequencing-by-synthesis reaction. In order to block misincorporation, nucleotide derivatives that hydrogen bond to their complement on the template, but do not engage in phosphodiester bonding with adjacent primer nucleotides, are added to the reaction along with labeled standard nucleotides for incorporation into the primer. A standard (labeled) nucleotide typically will out-compete derivatives for complementary binding. In cases in which a derivative attaches at an incorporation site intended for the complementary standard nucleotide, the derivative will be washed out and the position will be occupied by a standard nucleotide in a subsequent round. Because a complementary derivative will typically out-compete a mismatched standard nucleotide for incorporation, the derivatives end up blocking misincorporation. Derivatives, which are only hydrogen-bonded to their complement, are labile in comparison to standard nucleotides, which engage in phosphodiester bonding to adjacent primer nucleotides (in addition to complement hydrogen bonding). Thus derivatives can be washed out, making their complement available for binding in subsequent nucleotide addition cycle.


Methods of the invention prevent some or all of the misincorporation errors that result in erroneous base calling and/or chain termination in sequencing reactions. According to the invention, a polymerization reaction is conducted on a nucleic acid duplex that comprises a primer hybridized to a template nucleic acid. The reaction is conducted in the presence of a polymerase, at least one free dNTP corresponding to a first nucleotide species, and at least one nucleotide derivative corresponding to a nucleotide species different from the dNTP. The nucleotide derivative comprises a modification that inhibits the formation of a phosphodiester bond between the derivative and the free 3′ hydroxyl group of the terminal nucleotide on the primer. As such, the nucleotide derivative cannot incorporate into the primer. However, if the template comprises a nucleotide at a position immediately adjacent to the 3′ terminus of the primer that is complementary to the nucleotide derivative, the nucleotide derivative forms hydrogen bonds with its complementary nucleotide and prevents the incorporation of the free nucleotide into the primer. According to the invention, derivatives that are complementary to an available template nucleotide out-compete misincorporating dNTPs for template binding.


In a single molecule sequencing-by-synthesis reaction, primer/template duplexes are bound to a solid support such that each duplex is individually optically detectable. According to the invention, a primer/template duplex is exposed to a polymerase, a labeled nucleotide corresponding to at least a first nucleotide species, and at least one nucleotide derivative corresponding to a nucleotide species different than the labeled species. The duplex may be simultaneously exposed to the polymerase, labeled nucleotide and nucleotide derivative; or it may be first exposed to the nucleotide derivative and then to the polymerase and labeled nucleotide. In a preferred aspect, the duplex is simultaneously exposed to the polymerase, the free nucleotide and three nucleotide derivatives, one corresponding to each of the three remaining nucleotide species. Unincorporated labeled nucleotides are washed away, and because hydrogen bonds are relatively weak, the nucleotide derivatives are removed along with the unincorporated labeled nucleotides. The incorporation of the labeled nucleotide is determined, as well the identity of the nucleotide that is complementary to a nucleotide on the template at a position that is opposite the incorporated nucleotide. The polymerization reaction is serially repeated in the presence of labeled nucleotide that corresponds to each of the other nucleotide species, and appropriate nucleotide derivatives, until a sequence of incorporated nucleotides is compiled from which the sequence of the template nucleic acid can be determined.


Single molecule sequencing methods of the invention preferably comprise template/primer duplex attached to a surface. Individual nucleotides added to the surface comprise a detectable label—preferably a fluorescent label. Each nucleotide species can comprise a different label, or they can comprise the same label. In a preferred embodiment, each duplex is individually optically resolvable in order to facilitate single molecule sequence discrimination. The choice of a surface for attachment of duplex depends upon the detection method employed. Preferred surfaces for methods of the invention include epoxide surfaces and polyelectrolyte multilayer surfaces, such as those described in Braslavsky, et al., supra. Surfaces preferably are deposited on a substrate that is amenable to optical detection of the surface chemistry, such as glass or silica. The precise surface and substrate used in methods of the invention is immaterial to the functioning of the invention.


The invention provides also compositions for use in a nucleic acid synthesis reaction. In one embodiment, the compositions comprise labeled nucleotide corresponding to a first nucleotide species and at least one nucleotide derivative corresponding to a different nucleotide sequence. Methods and compositions of the invention may take into account that different nucleotides incorporate in an extending primer at different rates and that misincorporation rates similarly vary with the type of nucleotide being incorporated. Accordingly, the identity of the one or more nucleotide derivatives used in methods and compositions of the invention can be varied with the identity of the correct nucleotide sought to be incorporated. For example, if guanidine triphosphate frequently misincorporates at an incorporation site in which adenosine triphosphate should be incorporated, but never misincorporates at an incorporation site in which thymidine triphosphate or cytidine triphosphate should be incorporated, there is no need to add nucleotide derivatives corresponding to thymidine triphosphate or cytidine triphosphate in a synthesis reaction in which guanidine triphosphate is used as the free nucleotide.


According to the invention, a nucleotide derivative forms a hydrogen bond with a complementary nucleotide on a template nucleic acid, but comprises a modification that prohibits the polymerase from incorporating the derivative into the primer because it prevents the formation of a phosphodiester bond with the 3′ hydroxyl group of the primer. Preferred nucleotide derivatives comprise a modification to the normal nucleotide triphosphate group to prevent formation of a phosphodiester bond. Preferably, the oxygen bridging the α- and β-phosphates is replaced with another molecule that prevents formation of the phosphodiester bond. Particularly preferred derivatives comprise a substitution of the oxygen molecule bridging the α- and β-phosphate with a carbon, nitrogen or sulfur molecule or a methylene group. Other nucleotide derivatives useful in the invention comprise a modification of the α-, β- or γ-phosphate group. The modification may comprise, for example, the substitution of a bridging or non-bridging oxygen molecule with a thiol, alkyl, carbonyl, amine, alcohol, aryl or an animo acid group.


Nucleotides useful in the invention include any nucleotide or nucleotide analog, whether naturally-occurring or synthetic. For example, preferred nucleotides include phosphate esters of deoxyadenosine, deoxycytidine, deoxyguanosine, deoxythymidine, adenosine, cytidine, guanosine, and uridine.


Polymerases useful in the invention include any nucleic acid polymerase capable of catalyzing a template-dependent addition of a nucleotide or nucleotide analog to a primer. Depending on the characteristics of the target nucleic acid, a DNA polymerase, an RNA polymerase, a reverse transcriptase, or a mutant or altered form of any of the foregoing can be used. According to one aspect of the invention, a thermophilic polymerase is used, such as ThermoSequenase®, 9oN™, Therminator™, Taq, Tne, Tma, Pfu, Tfl, Tth, Tli, Stoffel fragment, Vent™ and Deep Vent™ DNA polymerase.





BRIEF DESCRIPTION OF THE DRAWING


FIG. 1 is a schematic representation of a polymerization reaction that results in the addition of a nucleotide to a polynucleotide.



FIG. 2 is a schematic representation of a DNA synthesis reaction performed in the presence of a nucleotide derivative.





DETAILED DESCRIPTION

The invention provides methods and compositions for improving the fidelity of a nucleic acid sequencing-by-synthesis reaction by reducing misincorporation of nucleotides. While applicable to bulk sequencing methods, the invention is particularly useful in connection with single molecule sequencing methods. Methods of the invention improve the fidelity of DNA synthesis by blocking misincorporation of a nucleotide triphosphate in template/primer duplexes. According to the invention, when DNA synthesis reaction is performed in the presence of a nucleotide derivative that is complementary to the template nucleotide, the nucleotide derivative forms hydrogen bonds with the template nucleotide, but does not form a phosphodiester bond with the 3′ hydroxyl group of the primer. Without incorporating into the primer, the nucleotide derivative is transiently held in place by the hydrogen bonds and blocks the misincorporation of the nucleotide triphosphate.



FIG. 2 is a schematic representation of DNA synthesis reaction in which a nucleotide derivative (as shown α,β-S-2′-deoxyadenosine 5′-triphosphate) (10) has formed hydrogen bonds with its complementary base (12) located on the template (14) opposite the incorporation site immediately adjacent the 3′ terminus of the primer (16). Because the nucleotide derivative lacks an oxygen molecule bridging the α and β phosphate groups, the polymerase (18) is not able to catalyze the formation of a phosphodiester bond between the nucleotide derivative (10) and the 3′ hydroxyl group of the primer (16), but because the derivative (10) is blocking the incorporation site at the 3′ terminus of the primer (16), the polymerase (18) can not misincorporate an incorrect (i.e., non-complementary) nucleotide (20).


According to the invention, a polymerization reaction is conducted in the presence of a polymerase, at least one labeled dNTP corresponding to a first nucleotide species, and at least one nucleotide derivative corresponding to a different nucleotide species. The nucleotide derivative comprises a modification that inhibits the formation of a phosphodiester bond between the derivative and the 3′ hydroxyl group of a primer on a primer/template duplex. If the template comprises a nucleotide opposite the incorporation site that is not complementary to the dNTP, but is complementary to the nucleotide derivative, the polymerase recognizes the nucleotide derivative as complementary to the template nucleotide and brings the derivative into close proximity with the template nucleotide, which facilitates the formation of hydrogen bonds between the derivative and its complementary nucleotide. With the nucleotide derivative blocking the incorporation site, misincorporation of the dNTP is prevented.


Methods and compositions of the invention are particularly well-suited for use in single molecule sequencing techniques. Substrate-bound primer/template duplexes are exposed to a polymerase, a labeled nucleotide corresponding to a first nucleotide species, and at least one nucleotide derivative corresponding to a different nucleotide species. The duplex may be simultaneously exposed to the polymerase, the labeled nucleotide, and the nucleotide derivative; or it may be first exposed to the nucleotide derivative and then to the polymerase and labeled nucleotide. Typically, however, the duplex is simultaneously exposed to the polymerase, the labeled nucleotide, and three nucleotide derivatives, one corresponding to each of the three remaining nucleotide species. The duplexes are washed of unincorporated labeled nucleotides and nucleotide derivatives, and the incorporation of labeled nucleotide is determined. The identity of the nucleotide positioned on the template opposite the incorporate nucleotide is likewise determined. The polymerization reaction is serially repeated in the presence of a labeled nucleotide that corresponds to each of the other nucleotide species in order to compile a sequence of incorporated nucleotides that is representative of the complement to the template nucleic acid.


Certain non-limiting aspects of the invention are further described below in terms of general considerations and examples.


I. General Considerations


A. Nucleotides


Nucleotides useful in the invention as free, unbound nucleotides for incorporation into a primer/template duplex include any nucleotide or nucleotide analog, whether naturally-occurring or synthetic. For example, preferred nucleotides include phosphate esters of deoxyadenosine, deoxycytidine, deoxyguanosine, deoxythymidine, adenosine, cytidine, guanosine, and uridine. Other nucleotides useful in the invention comprise an adenine, cytosine, guanine, thymine base, an xanthine or hypoxanthine; 5-bromouracil, 2-aminopurine, deoxyinosine, or methylated cytosine, such as 5-methylcytosine, and N4-methoxydeoxycytosine. Also included are bases of polynucleotide mimetics, such as methylated nucleic acids, e.g., 2′-O-methRNA, peptide nucleic acids, modified peptide nucleic acids, locked nucleic acids and any other structural moiety that can act substantially like a nucleotide or base, for example, by exhibiting base-complementarity with one or more bases that occur in DNA or RNA and/or being capable of base-complementary incorporation, and includes chain-terminating analogs. A nucleotide corresponds to a specific nucleotide species if they share base-complementarity with respect to at least one base.


Nucleotides for nucleic acid sequencing according to the invention preferably comprise a detectable label. Labeled nucleotides include any nucleotide that has been modified to include a label that is directly or indirectly detectable. Preferred labels include optically-detectable labels, including fluorescent labels or fluorophores, such as fluorescein, rhodamine, derivatized rhodamine dyes, such as TAMRA, phosphor, polymethadine dye, fluorescent phosphoramidite, Texas Red, green fluorescent protein, acridine, cyanine, cyanine 5 dye, cyanine 3 dye, 5-(2′-aminoethyl)-aminonaphthalene-1-sulfonic acid (EDANS), BODIPY, 120 ALEXA or a derivative or modification of any of the foregoing, and also include such labeling systems as hapten labeling. Accordingly, methods of the invention further provide for exposing the primer/target nucleic acid duplex to a digoxigenin, a fluorescein, an alkaline phosphatase or a peroxidase.


B. Nucleotide Derivatives


Nucleotide derivatives useful in the invention include any nucleotide, including those described above in Section A, that forms hydrogen bonds with a complementary nucleotide on a template nucleic acid, but comprises a modification that prevents the formation of a phosphodiester bond with the 3′ hydroxyl group of the primer. Preferred nucleotide derivatives will be recognized by the catalytic domain of the polymerase and brought in close proximity with its complementary nucleotide where hydrogen bonding can occur. Accordingly, particularly useful nucleotide derivatives most closely resemble naturally-occurring substrates for polymerases in both chemical formula and structure. Thus, particularly useful nucleotide derivatives comprise phosphate esters of deoxyadenosine, deoxycytidine, deoxyguanosine, deoxythymidine, adenosine, cytidine, guanosine, and uridine. In a preferred embodiment, nucleotide derivatives comprise a triphosphate ester, such as dATP, dCTP, dGTP, dTTP or dUTP. A nucleotide derivative corresponds to a specific nucleotide species if they exhibit the same base-complementarity with respect to at least one base.


According to one feature, a nucleotide derivative comprises a modification of the oxygen bridging the α-phosphate and the β-phosphate in a standard nucleotide triphosphate. For example, preferred modifications include the substitution of the oxygen molecule bridging the α- and β-phosphate groups with a carbon, nitrogen or sulfur molecule or a methylene group. Other nucleotide derivatives useful in the invention comprise a modification of the α-, β- or γ-phosphate group, such as, for example, the substitution of a bridging or non-bridging oxygen molecule with a thiol, alkyl, carbonyl, amine, alcohol, aryl or an animo acid group; or a bulky group that physically interferes with polymerase function. Custom modified nucleotides are commercially available from, for example, TriLink BioTechnologies, Inc., San Diego, Calif., Alexis Biochemicals, Inc., Carlsbad, Calif. and BIOLOG Life Science Institute, Germany.


C. Nucleic Acid Polymerases


Nucleic acid polymerases generally useful in the invention include DNA polymerases, RNA polymerases, reverse transcriptases, and mutant or altered forms of any of the foregoing. DNA polymerases and their properties are described in detail in, among other places, DNA Replication 2nd edition, Komberg and Baker, W. H. Freeman, New York, N.Y. (1991). Known conventional DNA polymerases useful in the invention include, but are not limited to, Pyrococcus furiosus (Pfu) DNA polymerase (Lundberg et al., 1991, Gene, 108: 1, Stratagene), Pyrococcus woesei (Pwo) DNA polymerase (Hinnisdaels et al., 1996, Biotechniques, 20:186-8, Boehringer Mannheim), Thermus thermophilus (Tth) DNA polymerase (Myers and Gelfand 1991, Biochemistry 30:7661), Bacillus stearothermophilus DNA polymerase (Stenesh and McGowan, 1977, Biochim Biophys Acta 475:32), Thermococcus litoralis (Tli) DNA polymerase (also referred to as Vent™ DNA polymerase, Cariello et al., 1991, Polynucleotides Res, 19: 4193, New England Biolabs), 9oNm™ DNA polymerase (New England Biolabs), Stoffel fragment, ThermoSequenase® (Amersham Pharmacia Biotech UK), Therminator™ (New England Biolabs), Thermotoga maritima (Tma) DNA polymerase (Diaz and Sabino, 1998 Braz J Med. Res, 31:1239), Thermus aquaticus (Taq) DNA polymerase (Chien et al., 1976, J. Bacteoriol, 127: 1550), DNA polymerase, Pyrococcus kodakaraensis KOD DNA polymerase (Takagi et al., 1997, Appl. Environ. Microbiol. 63:4504), JDF-3 DNA polymerase (from thermococcus sp. JDF-3, Patent application WO 0132887), Pyrococcus GB-D (PGB-D) DNA polymerase (also referred as Deep Vent™ DNA polymerase, Juncosa-Ginesta et al., 1994, Biotechniques, 16:820, New England Biolabs), UlTma DNA polymerase (from thermophile Thermotoga maritima; Diaz and Sabino, 1998 Braz J. Med. Res, 31:1239; PE Applied Biosystems), Tgo DNA polymerase (from thermococcus gorgonarius, Roche Molecular Biochemicals), E. coli DNA polymerase I (Lecomte and Doubleday, 1983, Polynucleotides Res. 11:7505), T7 DNA polymerase (Nordstrom et al., 1981, J Biol. Chem. 256:3112), and archaeal DP1I/DP2 DNA polymerase II (Cann et al., 1998, Proc Natl Acad. Sci. USA 95:14250-->5).


While mesophilic polymerases are contemplated by the invention, preferred polymerases are thermophilic. Thermophilic DNA polymerases include, but are not limited to, ThermoSequenase®, 9oNm™, Therminator™, Taq, Tne, Tma, Pfu, Tfl, Tth, Tli, Stoffel fragment, Vent™ and Deep Vent™ DNA polymerase, KOD DNA polymerase, Tgo, JDF-3, and mutants, variants and derivatives thereof.


Reverse transcriptases useful in the invention include, but are not limited to, reverse transcriptases from HIV, HTLV-1, HTLV-II, FeLV, FIV, SIV, AMV, MMTV, MoMuLV and other retroviruses (see Levin, Cell 88:5-8 (1997); Verma, Biochim Biophys Acta. 473:1-38 (1977); Wu et al., CRC Crit Rev Biochem. 3:289-347 (1975)).


Certain embodiments of the invention are described in the following examples, which are not meant to be limiting.


EXAMPLE 1
Single Molecule Sequencing Using Nucleotide Derivatives

The following nucleotide derivatives, each comprising a substitution of the oxygen molecule bridging the α and β phosphate groups with a sulfur molecule, are prepared: α,β-S-2′-deoxyadenosine 5′-triphosphate; α,β-S-2′-deoxycytidine 5′-triphosphate; α,β-S-2′-deoxyguanosine 5′-triphosphate; and α,β-S-2′-deoxythymidine 5′-triphosphate. Primer/template duplexes are bound to a solid support in a concentration that results in individually optically resolvable duplexes. The bound duplexes are subjected to serial sequencing-by-synthesis cycles in which a polymerase, labeled standard nucleotide, and nucleotide derivatives corresponding to each of the three non-standard nucleotide species are combined. The incorporation of a labeled nucleotide is determined, recorded and the reaction serially repeated with labeled nucleotide corresponding to each of the different nucleotide species and the appropriate nucleotide derivatives in order to compile a sequence that is representative of the complement of the target nucleic acid.


EXAMPLE 2
Assay for the Inhibition of Polymerase Activity

A simple assay may be performed to assess the ability of a usefulness of nucleotide derivative in methods and compositions of the invention.


Primed DNA template is diluted into an appropriate volume of 20 mM Tris-HCl, pH 7.5 and the enzyme is diluted into an appropriate volume of 20 mM Tris-HCl, containing 2 mM β-mercaptoethanol, and 100 mM KCl. 0.05 mg/mL primed DNA template and 0.01 U/μL DNA polymerase are pipetted into microcentrifuge tubes or a 96-well plate in a 50 μL reaction volume. 1.6 μM nucleotide derivative is added to the test reactions. Blank reactions excluding enzyme and control reactions excluding test compound are also prepared using enzyme dilution buffer and test compound solvent, respectively. The reaction is initiated with reaction buffer with the following components 20 mM Tris-HCl, pH 7.5; 200 μg/mL bovine serum albumin; 100 mM KCl; 2 mM β-mercaptoethanol; 10 mM MgCl2, 1.6 μM dATP, dGTP, dCTP, and dTTP; and α-33P-dAT. The reaction is incubated for sixty minutes at 37° C. and then quenched by the addition of 20 μL of 0.5M EDTA. 50 μL of the quenched reaction is spotted onto Whatman DE81 filter disks and air dried. The filter disks are repeatedly washed with 150 mL 0.3M ammonium formate, pH 8 until 1 mL of wash is <100 cpm. The disks are washed twice with 150 mL absolute ethanol and once with 150 mL anhydrous ether, dried and counted in 5 mL scintillation fluid.


The percentage of inhibition of the test is calculated according to the following equation: % inhibition={1−(cpm in test reaction−cpm in blank)/(cpm in control reaction−cpm in blank)}×100.


The invention may be embodied in other specific forms without departing from the spirit or essential characteristics thereof. The foregoing embodiments are therefore to be considered in all respects illustrative rather than limiting on the invention described herein. Scope of the invention is thus indicated by the appended claims rather than by the foregoing description, and all changes which come within the meaning and range of equivalency of the claims are therefore intended to be embraced therein

Claims
  • 1. A method for inhibiting nucleotide misincorporation in a nucleic acid synthesis reaction, the method comprising conducting a polymerization reaction on a nucleic acid duplex comprising a template and a primer in the presence of a nucleic acid polymerase, a first detectably labeled nucleotide corresponding to a first nucleotide species complementary to the position opposite the incorporation site at the 3′ terminus of the primer,a second nucleotide of a different species, andat least one nucleotide derivative, each of the nucleotide derivatives corresponding to a different nucleotide species than the first nucleotide species, wherein each nucleotide derivative comprises a modification that inhibits formation of a phosphodiester bond between the nucleotide derivative and a free 3′ hydroxyl on a primer nucleotide.
  • 2. The method of claim 1 further comprising removing nucleotide derivatives and nucleotides that are not incorporated into the primer.
  • 3. The method of claim 2 further comprising the step of repeating said conducting and removing steps using a second nucleotide species and a nucleotide derivative corresponding to a nucleotide species different from said second species.
  • 4. The method of claim 1 wherein said nucleotide derivative comprises a triphosphate group lacking an oxygen between an α-phosphate and a β-phosphate such that said nucleotide derivative is prevented from forming a phosphodiester bond with said free 3′ hydroxyl group on the primer.
  • 5. The method of claim 4 wherein said derivative comprises substitution of an oxygen molecule with a carbon, nitrogen or sulfur molecule.
  • 6. The method of claim 4 wherein said derivative comprises substitution of an oxygen molecule with a methylene group.
  • 7. The method of claim 4 wherein said derivative comprises substitution of an oxygen molecule with a thiol, alkyl, carbonyl, amine, alcohol, aryl or an amino acid group.
  • 8. The method of claim 1 wherein, if said template comprises a nucleotide opposite a position immediately adjacent to a 3′ terminus of the primer that is complementary to said nucleotide derivative but not complementary to said first nucleotide, said nucleotide derivative forms a hydrogen bond with its complementary nucleotide so as to prevent said first nucleotide from bonding thereto and misincorporating into said primer in said nucleic acid synthesis reaction.
  • 9. The method of claim 1 wherein said nucleic acid duplex is bound to a solid support.
  • 10. The method of claim 1 comprising a plurality of said duplex, each member of said plurality being individually optically resolvable.
  • 11. A method for sequencing a nucleic acid, the method comprising the steps of: (a) exposing a nucleic acid duplex comprising a template and a primer to a nucleic acid polymerase, a first labeled nucleotide, and at least one nucleotide derivative corresponding to a nucleotide species different from said first nucleotide; wherein said nucleotide derivative comprises a modification that inhibits formation of a phosphodiester bond between the nucleotide derivative and a 3′ hydroxyl group of the primer, and (b) removing nucleotide derivatives and labeled nucleotides that are not incorporated into the primer; (c) determining incorporation of the labeled nucleotide and thereby identifying a nucleotide that is complementary to a nucleotide at a position on said template opposite the incorporated labeled nucleotide; and (d) repeating steps (a), (b) and (c) with a second labeled nucleotide and at least one nucleotide derivative corresponding to a nucleotide species different from said second labeled nucleotide.
  • 12. The method of claim 11 wherein said nucleotide derivative comprises a triphosphate group having a molecule other than oxygen between an α-phosphate and β-phosphate.
  • 13. The method of claim 12 wherein said derivative comprises substitution of an oxygen molecule with a carbon, nitrogen or sulfur molecule.
  • 14. The method of claim 12 wherein said derivative comprises a substitution of an oxygen molecule with a methylene group.
  • 15. The method of claim 2 wherein said nucleotide derivative comprises a triphosphate group having a modified α- or β-phosphate.
  • 16. The method of claim 15 wherein said modification comprises a substitution of an oxygen molecule with a thiol, alkyl, carbonyl, amine, alcohol, aryl or an amino acid group.
  • 17. The method of claim 11 wherein said exposing step is performed in the presence of at least two nucleotide derivatives, each derivative corresponding to a nucleotide species different from said first nucleotide.
  • 18. The method of claim 11 wherein said exposing step is performed in the presence of three nucleotide derivatives, each derivative corresponding to a nucleotide species different from said first nucleotide.
  • 19. The method of claim 11 further comprising the step of compiling a sequence of nucleotides incorporated into said primer.
  • 20. The method of claim 11 wherein said labeled nucleotide comprises a labeled dNTP.
  • 21. The method of claim 11 wherein said first nucleotide is a deoxyadenosine triphosphate and said at least one nucleotide derivative corresponds to a nucleotide species selected from the group consisting of deoxyguanosine triphosphate, deoxycytidine triphosphate, and deoxyuridine triphosphate.
  • 22. The method of claim 11 wherein said first nucleotide is a deoxyguanosine triphosphate thereof and said at least one nucleotide derivative corresponds to a nucleotide species selected from the group consisting of deoxyadenosine triphosphate, deoxycytidine triphosphate and deoxyuridine triphosphate.
  • 23. The method of claim 11 wherein said first nucleotide is a deoxycytidine triphosphate thereof and said three nucleotide derivatives corresponds to the nucleotide species of deoxyadenosine triphosphate, deoxyguanosine triphosphate and deoxyuridine triphosphate.
  • 24. The method of claim 11 wherein said first nucleotides is a deoxyuridine triphosphate thereof and said at least one nucleotide derivative corresponds to a nucleotide species selected from the group consisting of deoxyadenosine triphosphate, deoxyguanosine triphosphate and deoxycytidine triphosphate.
  • 25. The method of claim 18 wherein said first nucleotide is a deoxyadenosine triphosphate thereof and said three nucleotide derivatives correspond to deoxyguanosine triphosphate, deoxycytidine triphosphate, and deoxyuridine triphosphate.
  • 26. The method of claim 18 wherein said first nucleotide is a deoxyguanosine triphosphate and said three nucleotide derivatives correspond to deoxyadenosine triphosphate, deoxycytidine triphosphate and deoxyuridine triphosphate.
  • 27. The method of claim 18 wherein said first nucleotide is a deoxycytidine triphosphate and said three nucleotide derivatives correspond to deoxyadenosine triphosphate, deoxyguanosine triphosphate and deoxyuridine triphosphate.
  • 28. The method of claim 18 wherein said first nucleotide is a deoxyuridine triphosphate and said three nucleotide derivatives correspond to deoxyadenosine triphosphate, deoxyguanosine triphosphate and deoxycytidine triphosphate.
  • 29. The method of claim 11, wherein said exposing step comprises first exposing said nucleic acid duplex to said at least one nucleotide derivative, then exposing said nucleic acid duplex to said nucleic acid polymerase and said labeled nucleotide.
  • 30. The method of claim 1 wherein the polymerization reaction is conducted in the presence of three different species of nucleotide derivatives.
US Referenced Citations (436)
Number Name Date Kind
3996345 Ullman et al. Dec 1976 A
4119368 Yamazaki Oct 1978 A
4153855 Feingold May 1979 A
4344064 Bitler et al. Aug 1982 A
4351760 Khanna et al. Sep 1982 A
4683195 Mullis et al. Jul 1987 A
4683202 Mullis Jul 1987 A
4707237 Lepp et al. Nov 1987 A
4711955 Ward et al. Dec 1987 A
4725677 Koster et al. Feb 1988 A
4739044 Stabinsky Apr 1988 A
4757141 Fung et al. Jul 1988 A
4793705 Shera Dec 1988 A
4811218 Hunkapiller et al. Mar 1989 A
4863849 Melamede Sep 1989 A
4865968 Orgel et al. Sep 1989 A
4889818 Gelfand et al. Dec 1989 A
4942124 Church Jul 1990 A
4962037 Jett et al. Oct 1990 A
4971903 Hyman Nov 1990 A
4979824 Mathies et al. Dec 1990 A
4994368 Goodman et al. Feb 1991 A
4994372 Tabor et al. Feb 1991 A
4994373 Stavrianopoulos et al. Feb 1991 A
5085562 van Lintel Feb 1992 A
5091652 Mathies et al. Feb 1992 A
5096388 Weinberg Mar 1992 A
5096554 Chin et al. Mar 1992 A
5108892 Burke et al. Apr 1992 A
5112736 Caldwell et al. May 1992 A
RE34069 Koster et al. Sep 1992 E
5143854 Pirrung et al. Sep 1992 A
5167784 Noolandi Dec 1992 A
5171132 Miyazaki et al. Dec 1992 A
5198540 Koster Mar 1993 A
5209834 Shera May 1993 A
5224843 van Lintel Jul 1993 A
5242796 Prober et al. Sep 1993 A
5242797 Hirschfeld Sep 1993 A
5258506 Urdea et al. Nov 1993 A
5259737 Kamisuki et al. Nov 1993 A
5260433 Engelhardt et al. Nov 1993 A
5265327 Faris et al. Nov 1993 A
5267152 Yang et al. Nov 1993 A
5302509 Cheeseman Apr 1994 A
5304487 Wilding et al. Apr 1994 A
5306403 Vo-Dinh Apr 1994 A
5336062 Richter Aug 1994 A
5360523 Middendorf et al. Nov 1994 A
5375979 Trah Dec 1994 A
5376252 Ekstrom et al. Dec 1994 A
5403709 Agrawal et al. Apr 1995 A
5405747 Jett et al. Apr 1995 A
5405783 Pirrung et al. Apr 1995 A
5409811 Tabor et al. Apr 1995 A
5424186 Fodor et al. Jun 1995 A
5436149 Barnes Jul 1995 A
5449767 Ward et al. Sep 1995 A
5476928 Ward et al. Dec 1995 A
5484701 Cocuzza et al. Jan 1996 A
5492806 Drmanac et al. Feb 1996 A
5514256 Douthart et al. May 1996 A
5518900 Nikiforov et al. May 1996 A
5525464 Drmanac et al. Jun 1996 A
5529465 Zengerle et al. Jun 1996 A
5534125 Middendorf et al. Jul 1996 A
5547839 Dower et al. Aug 1996 A
5547859 Goodman et al. Aug 1996 A
5556790 Pettit Sep 1996 A
5558991 Trainor Sep 1996 A
5599695 Pease et al. Feb 1997 A
5610287 Nikiforov et al. Mar 1997 A
5631734 Stern et al. May 1997 A
5632957 Heller et al. May 1997 A
5654149 Mendoza et al. Aug 1997 A
5659171 Young et al. Aug 1997 A
5670346 Reeve et al. Sep 1997 A
5674716 Tabor et al. Oct 1997 A
5675155 Pentoney, Jr. et al. Oct 1997 A
5688648 Mathies et al. Nov 1997 A
5695940 Drmanac et al. Dec 1997 A
5705018 Hartley Jan 1998 A
5707506 Douthart et al. Jan 1998 A
5710628 Waterhouse et al. Jan 1998 A
5712476 Renfrew et al. Jan 1998 A
5733729 Lipshutz et al. Mar 1998 A
5741640 Fuller Apr 1998 A
5741644 Kambara et al. Apr 1998 A
5744305 Fodor et al. Apr 1998 A
5744312 Mamone et al. Apr 1998 A
5750341 Macevicz et al. May 1998 A
5753788 Fodor et al. May 1998 A
5755943 Middendorf et al. May 1998 A
5756285 Fuller May 1998 A
5759014 Van Lintel Jun 1998 A
5759374 Takahashi et al. Jun 1998 A
5762876 Lincoln et al. Jun 1998 A
5763594 Hiatt et al. Jun 1998 A
5776767 Stevens et al. Jul 1998 A
5776782 Tsuji Jul 1998 A
5789168 Leushner et al. Aug 1998 A
5795722 Lacroix et al. Aug 1998 A
5795782 Church et al. Aug 1998 A
5807679 Kamb Sep 1998 A
5808045 Hiatt et al. Sep 1998 A
5830657 Leushner et al. Nov 1998 A
5831070 Pease et al. Nov 1998 A
5832165 Reichert et al. Nov 1998 A
5834758 Trulson et al. Nov 1998 A
5836750 Cabuz Nov 1998 A
5837832 Chee et al. Nov 1998 A
5837860 Anderson et al. Nov 1998 A
5846396 Zanzucchi et al. Dec 1998 A
5846727 Soper et al. Dec 1998 A
5853979 Green et al. Dec 1998 A
5858671 Jones Jan 1999 A
5861287 Metzker et al. Jan 1999 A
5863722 Brenner Jan 1999 A
5872244 Hiatt et al. Feb 1999 A
5876187 Afromowitz et al. Mar 1999 A
5876934 Duthie et al. Mar 1999 A
5882904 Riedl et al. Mar 1999 A
5885813 Davis et al. Mar 1999 A
5889165 Fodor et al. Mar 1999 A
5902723 Dower et al. May 1999 A
5908755 Kumar et al. Jun 1999 A
5916747 Gilchrist et al. Jun 1999 A
5922591 Anderson et al. Jul 1999 A
5922608 Farnsworth et al. Jul 1999 A
5928906 Koster et al. Jul 1999 A
5928919 Reha-Krantz et al. Jul 1999 A
5945283 Kwok et al. Aug 1999 A
5945284 Livak et al. Aug 1999 A
5945312 Goodman et al. Aug 1999 A
5945325 Arnold et al. Aug 1999 A
5948614 Chatterjee Sep 1999 A
5952174 Nikiforov et al. Sep 1999 A
5954932 Takahashi et al. Sep 1999 A
5958703 Dower et al. Sep 1999 A
5959781 Kintz et al. Sep 1999 A
5959837 Yu Sep 1999 A
5965446 Ishikawa Oct 1999 A
5968740 Fodor et al. Oct 1999 A
5974164 Chee Oct 1999 A
5976338 Fujita et al. Nov 1999 A
5976842 Wurst Nov 1999 A
5981186 Gabe et al. Nov 1999 A
5981956 Stern Nov 1999 A
5994058 Senapathy Nov 1999 A
5994085 Cantor Nov 1999 A
6002471 Quake Dec 1999 A
6005663 Waterhouse et al. Dec 1999 A
6007309 Hartley Dec 1999 A
6015714 Baldarelli et al. Jan 2000 A
6017702 Lee et al. Jan 2000 A
6018041 Drmanac et al. Jan 2000 A
6020457 Klimash et al. Feb 2000 A
6024925 Little et al. Feb 2000 A
6025136 Drmanac Feb 2000 A
6028190 Mathies et al. Feb 2000 A
6030782 Anderson et al. Feb 2000 A
6043080 Lipshutz et al. Mar 2000 A
6046005 Ju et al. Apr 2000 A
6049380 Goodwin et al. Apr 2000 A
6051380 Sosnowski et al. Apr 2000 A
6066454 Lipshutz et al. May 2000 A
6071394 Cheng et al. Jun 2000 A
6077664 Slater et al. Jun 2000 A
6077674 Schleifer et al. Jun 2000 A
6087095 Rosenthal et al. Jul 2000 A
6087099 Gupte et al. Jul 2000 A
6094274 Yokoi Jul 2000 A
6107032 Kilger et al. Aug 2000 A
6107044 Nikiforov Aug 2000 A
6107061 Johnson Aug 2000 A
6132580 Mathies et al. Oct 2000 A
6133436 Koster et al. Oct 2000 A
6136212 Mastrangelo et al. Oct 2000 A
6136962 Shi et al. Oct 2000 A
6140053 Koster Oct 2000 A
6140494 Hamilton et al. Oct 2000 A
6141096 Stern et al. Oct 2000 A
6143151 Middendorf et al. Nov 2000 A
6147205 McGall et al. Nov 2000 A
6156501 McGall et al. Dec 2000 A
6165694 Liu Dec 2000 A
6177249 Kwok et al. Jan 2001 B1
6197506 Fodor et al. Mar 2001 B1
6197595 Anderson et al. Mar 2001 B1
6207381 Larsson et al. Mar 2001 B1
6207960 Stern Mar 2001 B1
6210896 Chan Apr 2001 B1
6214246 Craighead Apr 2001 B1
6214987 Hiatt et al. Apr 2001 B1
6221592 Schwartz et al. Apr 2001 B1
6221654 Quake et al. Apr 2001 B1
6225052 Batz et al. May 2001 B1
6225062 Dunn et al. May 2001 B1
6225092 Kilger et al. May 2001 B1
6225109 Juncosa et al. May 2001 B1
6225567 Kester May 2001 B1
6225625 Pirrung et al. May 2001 B1
6228593 Lipshutz et al. May 2001 B1
6232075 Williams May 2001 B1
6232103 Short May 2001 B1
6235465 Kolberg et al. May 2001 B1
6235473 Friedman et al. May 2001 B1
6242180 Chee Jun 2001 B1
6242528 Clark et al. Jun 2001 B1
6245506 Laugharn, Jr. et al. Jun 2001 B1
6245507 Bogdanov Jun 2001 B1
6245518 Baier Jun 2001 B1
6251610 Gupte et al. Jun 2001 B1
6255083 Williams Jul 2001 B1
6255475 Kwiatkowski Jul 2001 B1
6258533 Jones Jul 2001 B1
6261775 Bastian et al. Jul 2001 B1
6261776 Pirrung et al. Jul 2001 B1
6261848 Anderson et al. Jul 2001 B1
6262838 Montagu Jul 2001 B1
6263286 Gilmanshin et al. Jul 2001 B1
6268152 Fodor et al. Jul 2001 B1
6268219 Mcbride et al. Jul 2001 B1
6269846 Overbeck et al. Aug 2001 B1
6270644 Mathies et al. Aug 2001 B1
6270961 Drmanac Aug 2001 B1
6274320 Rothberg et al. Aug 2001 B1
6274351 Peponnet Aug 2001 B1
6277604 Peponnet Aug 2001 B1
6280954 Ulfendahl Aug 2001 B1
6284460 Fodor et al. Sep 2001 B1
6287821 Shi et al. Sep 2001 B1
6294336 Boyce-Jacino et al. Sep 2001 B1
6294337 Hayashizaki Sep 2001 B1
6306607 Williams Oct 2001 B2
6309601 Juncosa et al. Oct 2001 B1
6309701 Barbera-Guillem Oct 2001 B1
6309824 Drmanac Oct 2001 B1
6309836 Kwiatkowski Oct 2001 B1
6309886 Ambrose et al. Oct 2001 B1
6310189 Fodor et al. Oct 2001 B1
6312893 Van Ness et al. Nov 2001 B1
6316191 Drmanac et al. Nov 2001 B1
6322968 Head et al. Nov 2001 B1
6331439 Cherukuri et al. Dec 2001 B1
6333183 Evans et al. Dec 2001 B1
6335824 Overbeck Jan 2002 B1
6337185 Asp et al. Jan 2002 B1
6337188 Head et al. Jan 2002 B1
6342326 Milton Jan 2002 B1
6344325 Quake et al. Feb 2002 B1
6346379 Gelfand et al. Feb 2002 B1
6346413 Fodor et al. Feb 2002 B1
6355420 Chan Mar 2002 B1
6355432 Fodor et al. Mar 2002 B1
6361671 Mathies et al. Mar 2002 B1
6361937 Stryer Mar 2002 B1
6368562 Yao Apr 2002 B1
6368699 Gilbert et al. Apr 2002 B1
6383749 Bochkariov et al. May 2002 B2
6387626 Shi et al. May 2002 B1
6395232 McBride May 2002 B1
6395559 Swenson May 2002 B1
6397150 Izmailov May 2002 B1
6399364 Reeve et al. Jun 2002 B1
6401267 Drmanac Jun 2002 B1
6403311 Chan Jun 2002 B1
6403315 Drmanac Jun 2002 B1
6403317 Anderson Jun 2002 B1
6403320 Read et al. Jun 2002 B1
6403957 Fodor et al. Jun 2002 B1
6404907 Gilchrist et al. Jun 2002 B1
6406893 Knapp et al. Jun 2002 B1
6407858 Montagu Jun 2002 B1
6408878 Unger et al. Jun 2002 B2
6416952 Pirrung et al. Jul 2002 B1
6420169 Read et al. Jul 2002 B1
6423273 O'Mara Jul 2002 B1
6432634 Digby et al. Aug 2002 B1
6436641 Izmailov Aug 2002 B1
6436646 Nikiforov Aug 2002 B1
6440664 Digby et al. Aug 2002 B1
6440722 Knapp et al. Aug 2002 B1
6444106 Mcbride et al. Sep 2002 B1
6444173 Sjursen et al. Sep 2002 B1
6444424 Chatterjee et al. Sep 2002 B1
6444461 Knapp et al. Sep 2002 B1
6447724 Jensen et al. Sep 2002 B1
6448090 McBride Sep 2002 B1
6451536 Fodor et al. Sep 2002 B1
6479267 Davis et al. Nov 2002 B1
6485690 Pfost et al. Nov 2002 B1
6485909 Hong et al. Nov 2002 B1
6485944 Church et al. Nov 2002 B1
6495363 Bogdanov Dec 2002 B2
6506560 Hughes et al. Jan 2003 B1
6511803 Church et al. Jan 2003 B1
6514706 Von Kalle et al. Feb 2003 B1
6521428 Senapathy Feb 2003 B1
6524829 Seeger Feb 2003 B1
6528258 Russell Mar 2003 B1
6528288 Senapathy Mar 2003 B2
6537755 Drmanac Mar 2003 B1
6537757 Langmore et al. Mar 2003 B1
6546340 Lipshutz et al. Apr 2003 B2
6551784 Fodor et al. Apr 2003 B2
6551817 Besemer et al. Apr 2003 B2
6554987 Gilchrist et al. Apr 2003 B1
6555349 O'Donnell Apr 2003 B1
6558945 Kao May 2003 B1
6562566 Hoheisel May 2003 B1
6566059 Stanton, Jr. et al. May 2003 B1
6566515 McGall et al. May 2003 B1
6573047 Hung et al. Jun 2003 B1
6573374 Muehlegger et al. Jun 2003 B1
6576424 Fodor et al. Jun 2003 B2
6576425 McGall et al. Jun 2003 B2
6579704 Short Jun 2003 B2
6582923 Stanton, Jr. et al. Jun 2003 B2
6585939 Dapprich Jul 2003 B1
6607888 Schwartz et al. Aug 2003 B2
6610482 Fodor et al. Aug 2003 B1
6613513 Parce et al. Sep 2003 B1
6623928 Van Ness et al. Sep 2003 B2
6627748 Ju et al. Sep 2003 B1
6632655 Mehta et al. Oct 2003 B1
6642001 Bolk et al. Nov 2003 B1
6664079 Ju et al. Dec 2003 B2
6719868 Schueller et al. Apr 2004 B1
6750018 Kambara et al. Jun 2004 B2
6762048 Williams Jul 2004 B2
6780591 Williams et al. Aug 2004 B2
6783938 Nygren et al. Aug 2004 B2
6787308 Balasubramanian et al. Sep 2004 B2
6818395 Quake et al. Nov 2004 B1
6908736 Densham Jun 2005 B1
6911345 Quake et al. Jun 2005 B2
20010024890 Kambara et al. Sep 2001 A1
20010044531 McGall et al. Nov 2001 A1
20010046681 Senapathy Nov 2001 A1
20020009744 Bogdanov Jan 2002 A1
20020012910 Weiss et al. Jan 2002 A1
20020015961 Kwiatkowski Feb 2002 A1
20020025529 Quake et al. Feb 2002 A1
20020032320 Burgess et al. Mar 2002 A1
20020034792 Kilger et al. Mar 2002 A1
20020039738 Williams et al. Apr 2002 A1
20020042112 Koster et al. Apr 2002 A1
20020045182 Singh et al. Apr 2002 A1
20020051992 Bridgham et al. May 2002 A1
20020053532 Quaker et al. May 2002 A1
20020061529 Bridgham et al. May 2002 A1
20020072055 Jones Jun 2002 A1
20020086318 Manalis et al. Jul 2002 A1
20020102586 Ju et al. Aug 2002 A1
20020102595 Davis Aug 2002 A1
20020106673 Drmanac et al. Aug 2002 A1
20020115076 Williams Aug 2002 A1
20020115092 Rebek, Jr. Aug 2002 A1
20020119484 Weidenhammer et al. Aug 2002 A1
20020123046 Smith et al. Sep 2002 A1
20020137046 Koster Sep 2002 A1
20020137052 Bridgham et al. Sep 2002 A1
20020137062 Williams et al. Sep 2002 A1
20020138205 Miller et al. Sep 2002 A1
20020142329 Matray et al. Oct 2002 A1
20020142333 Gelfand et al. Oct 2002 A1
20020146704 Head et al. Oct 2002 A1
20020146726 Matray et al. Oct 2002 A1
20020150903 Koster Oct 2002 A1
20020150938 Kneipp et al. Oct 2002 A1
20020164629 Quake et al. Nov 2002 A1
20020168642 Drukier Nov 2002 A1
20020168678 Williams et al. Nov 2002 A1
20020172948 Perlin Nov 2002 A1
20020177129 Paabo et al. Nov 2002 A1
20020182601 Sampson et al. Dec 2002 A1
20020192661 Paabo et al. Dec 2002 A1
20020192662 Boyce-Jacino et al. Dec 2002 A1
20020192691 Drmanac Dec 2002 A1
20020197618 Sampson Dec 2002 A1
20030003272 Laguitton Jan 2003 A1
20030003498 Digby et al. Jan 2003 A1
20030008285 Fischer Jan 2003 A1
20030008413 Kim et al. Jan 2003 A1
20030017461 Singh et al. Jan 2003 A1
20030022207 Balasubramanian et al. Jan 2003 A1
20030027140 Ju et al. Feb 2003 A1
20030036080 Jensen et al. Feb 2003 A1
20030044778 Goelet et al. Mar 2003 A1
20030044779 Goelet et al. Mar 2003 A1
20030044781 Korlach et al. Mar 2003 A1
20030044816 Denison et al. Mar 2003 A1
20030054181 Swerdlow et al. Mar 2003 A1
20030054361 Heller Mar 2003 A1
20030058440 Scott et al. Mar 2003 A1
20030058799 Yamakawa et al. Mar 2003 A1
20030059778 Berlin et al. Mar 2003 A1
20030060431 Simmonds et al. Mar 2003 A1
20030064366 Hardin et al. Apr 2003 A1
20030064398 Barnes Apr 2003 A1
20030064483 Shaw et al. Apr 2003 A1
20030087237 Hong et al. May 2003 A1
20030087300 Knapp et al. May 2003 A1
20030092005 Levene et al. May 2003 A1
20030092007 Gibbs et al. May 2003 A1
20030096258 Fu et al. May 2003 A1
20030100006 Senapathy May 2003 A1
20030104437 Barnes et al. Jun 2003 A1
20030104466 Knapp et al. Jun 2003 A1
20030108867 Chee et al. Jun 2003 A1
20030138809 Williams et al. Jul 2003 A1
20030148344 Rothberg et al. Aug 2003 A1
20030162213 Fuller et al. Aug 2003 A1
20030186227 Balasubramanian et al. Oct 2003 A1
20030186255 Williams et al. Oct 2003 A1
20030190627 Zhao et al. Oct 2003 A1
20030190647 Odera Oct 2003 A1
20030190663 Yang et al. Oct 2003 A1
20030194722 Odedra et al. Oct 2003 A1
20030194740 Williams Oct 2003 A1
20030215862 Wallace et al. Nov 2003 A1
20040009487 Kadushin et al. Jan 2004 A1
20040014096 Anderson et al. Jan 2004 A1
20040029115 Dower et al. Feb 2004 A9
20040038206 Zhang et al. Feb 2004 A1
20040054162 Hanna Mar 2004 A1
20040106110 Balasubramanian et al. Jun 2004 A1
20040110162 Lapidus et al. Jun 2004 A1
20040126770 Kumar et al. Jul 2004 A1
20050014175 Quake et al. Jan 2005 A1
20050100932 Lapidus et al. May 2005 A1
20050147992 Quake et al. Jul 2005 A1
20050170367 Quake et al. Aug 2005 A1
20050239085 Buzby et al. Oct 2005 A1
20060147935 Linnarsson Jul 2006 A1
Foreign Referenced Citations (176)
Number Date Country
10256898 Sep 2004 DE
0223618 May 1987 EP
0412883 Feb 1991 EP
0481065 Apr 1992 EP
0579997 Jan 1994 EP
0703364 Mar 1996 EP
0706004 Apr 1996 EP
0779436 Jun 1997 EP
0845603 Jun 1998 EP
0932700 Aug 1999 EP
0946752 Oct 1999 EP
0955085 Nov 1999 EP
0999055 May 2000 EP
0706004 Aug 2003 EP
2155152 Sep 1985 GB
2308460 Jun 1997 GB
2400518 Oct 2004 GB
9500589 Feb 1995 SE
8903432 Apr 1989 WO
8909283 Oct 1989 WO
9013666 Nov 1990 WO
9015070 Dec 1990 WO
9106678 May 1991 WO
9210092 Jun 1992 WO
9210587 Jun 1992 WO
9305183 Mar 1993 WO
9306121 Apr 1993 WO
9321340 Oct 1993 WO
9512608 May 1995 WO
9527080 Oct 1995 WO
9604547 Feb 1996 WO
9612014 Apr 1996 WO
9612039 Apr 1996 WO
9627025 Sep 1996 WO
9702488 Jan 1997 WO
9722076 Jun 1997 WO
9723650 Jun 1997 WO
9737041 Oct 1997 WO
9739150 Oct 1997 WO
9740184 Oct 1997 WO
9741258 Nov 1997 WO
9741259 Nov 1997 WO
9742348 Nov 1997 WO
9800708 Jan 1998 WO
9802575 Jan 1998 WO
9803684 Jan 1998 WO
9807069 Feb 1998 WO
9813523 Apr 1998 WO
9808978 May 1998 WO
9820019 May 1998 WO
9820020 May 1998 WO
9820166 May 1998 WO
9821361 May 1998 WO
9827228 Jun 1998 WO
9828440 Jul 1998 WO
9833939 Aug 1998 WO
9840520 Sep 1998 WO
9841650 Sep 1998 WO
9841657 Sep 1998 WO
9844152 Oct 1998 WO
9845481 Oct 1998 WO
9853300 Nov 1998 WO
9854669 Dec 1998 WO
9855593 Dec 1998 WO
9901768 Jan 1999 WO
9905221 Feb 1999 WO
9905315 Feb 1999 WO
9906422 Feb 1999 WO
9913109 Mar 1999 WO
9913110 Mar 1999 WO
9909616 Apr 1999 WO
9917093 Apr 1999 WO
9919516 Apr 1999 WO
9924797 May 1999 WO
9927137 Jun 1999 WO
9931278 Jun 1999 WO
9937810 Jul 1999 WO
9939001 Aug 1999 WO
9940105 Aug 1999 WO
9940223 Aug 1999 WO
9941410 Aug 1999 WO
0030591 Sep 1999 WO
9944045 Sep 1999 WO
9945153 Sep 1999 WO
9947539 Sep 1999 WO
9947706 Sep 1999 WO
9953423 Oct 1999 WO
9957321 Nov 1999 WO
9961888 Dec 1999 WO
9964437 Dec 1999 WO
9964840 Dec 1999 WO
9965938 Dec 1999 WO
9966076 Dec 1999 WO
9966313 Dec 1999 WO
0000637 Jan 2000 WO
0006770 Feb 2000 WO
0009753 Feb 2000 WO
0011223 Mar 2000 WO
0017397 Mar 2000 WO
0026935 May 2000 WO
0034523 Jun 2000 WO
0037680 Jun 2000 WO
0040750 Jul 2000 WO
0040758 Jul 2000 WO
0042223 Jul 2000 WO
0043540 Jul 2000 WO
0043752 Jul 2000 WO
0050642 Aug 2000 WO
0053805 Sep 2000 WO
0053812 Sep 2000 WO
0056937 Sep 2000 WO
0058507 Oct 2000 WO
0058516 Oct 2000 WO
0068410 Nov 2000 WO
0070073 Nov 2000 WO
0071755 Nov 2000 WO
0079007 Dec 2000 WO
01001025 Jan 2001 WO
0116375 Mar 2001 WO
0123610 Apr 2001 WO
0124937 Apr 2001 WO
0125480 Apr 2001 WO
0131055 May 2001 WO
0132930 May 2001 WO
0138574 May 2001 WO
0148184 May 2001 WO
0142496 Jun 2001 WO
0157248 Aug 2001 WO
0157249 Aug 2001 WO
0161044 Aug 2001 WO
0164838 Sep 2001 WO
0175154 Oct 2001 WO
0179536 Oct 2001 WO
0185991 Nov 2001 WO
0192284 Dec 2001 WO
0196607 Dec 2001 WO
0200343 Jan 2002 WO
0202584 Jan 2002 WO
0202795 Jan 2002 WO
0202813 Jan 2002 WO
0203305 Jan 2002 WO
0204680 Jan 2002 WO
0220836 Mar 2002 WO
0220837 Mar 2002 WO
0227032 Apr 2002 WO
0229106 Apr 2002 WO
0230486 Apr 2002 WO
0235441 May 2002 WO
0236832 May 2002 WO
0244414 Jun 2002 WO
WO 02244425 Jun 2002 WO
02061126 Aug 2002 WO
02061127 Aug 2002 WO
02072779 Sep 2002 WO
02072892 Sep 2002 WO
02077694 Oct 2002 WO
02079519 Oct 2002 WO
02088381 Nov 2002 WO
02088382 Nov 2002 WO
02097113 Dec 2002 WO
02099398 Dec 2002 WO
03002767 Jan 2003 WO
03016565 Feb 2003 WO
03020895 Mar 2003 WO
03020968 Mar 2003 WO
03021010 Mar 2003 WO
03031947 Apr 2003 WO
03044678 May 2003 WO
03048178 Jun 2003 WO
03048991 Jun 2003 WO
03062897 Jul 2003 WO
03106642 Dec 2003 WO
2004061119 Jul 2004 WO
2004074503 Sep 2004 WO
2005047523 May 2005 WO
2005080605 Sep 2005 WO
Related Publications (1)
Number Date Country
20060172313 A1 Aug 2006 US